DTB Podcast

April 2018: STOMP - time to make more noise

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a national campaign in England that is tackling the inappropriate use of antipsychotic and antidepressant medicines in people with learning or intellectual disability.
Read the article: http://dtb.bmj.com/content/56/4/37.
The editors also review the evidence for a once-daily triple inhaler for maintenance treatment for adults with moderate to severe COPD (http://dtb.bmj.com/content/56/4/42), and discuss off-label use of high-dose antihistamines for chronic spontaneous urticaria in adults (http://dtb.bmj.com/content/56/4/45).

March 2018: Do hypertension guidelines put the person first?

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss some of the difficulties in implementing clinical guidelines for the management of elevated blood pressure and the potential impact of changes in the threshold for a diagnosis of hypertension (http://dtb.bmj.com/content/56/3/25).
The editors also review the evidence for dupliumab for the treatment of moderate-to-severe atopic dermatitis in adults (http://dtb.bmj.com/content/56/3/30) and discuss drug names (http://dtb.bmj.com/content/56/3/33).
Read the full March 2018 issue here: http://dtb.bmj.com/content/56/3.

February 2018: Clinical guidelines - more PDAs please

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of developing patient decision aids to support the implementation of clinical guidelines (http://dtb.bmj.com/content/56/2/13).
The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).

January 2018: No alchemy for obesity

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of exercise, diet and behaviour modification in the management of obesity and consider the limitations of anti-obesity drugs. http://dtb.bmj.com/content/56/1/1
The editors also review the evidence for ▼patiromer, a cation exchange polymer, that has recently been marketed for the management of hyperkalaemia - http://dtb.bmj.com/content/56/1/6 and discuss the management of gout. http://dtb.bmj.com/content/56/1/9

December 2017: Shared care protocols – have they had their day?

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the challenge of prescribing specialist drugs in primary care and highlight problems associated with the use of shared care protocols. http://dtb.bmj.com/content/55/12/133
The editors also review the evidence for an inhaler containing beclometasone, formoterol and glycopyrronium that has recently been licensed for the management of COPD - http://dtb.bmj.com/content/55/12/138 - and discuss the use of dimethyl fumarate for psoriasis. http://dtb.bmj.com/content/55/12/141

November 2017: Prescribing in pregnancy - stop stopping and start planning

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the challenges associated with prescribing for long-term conditions in women who are pregnant and raise concerns that medicines may be stopped inappropriately. Read the editorial here: http://dtb.bmj.com/content/55/11/121.
The editors also review a combination product containing naltrexone and bupropion that is licensed for the management of obesity -
http://dtb.bmj.com/content/55/11/126 - and discuss bleeding risks
associated with direct oral anticoagulants (DOACs)- http://dtb.bmj.com/content/55/11/129.
http://dtb.bmj.com/

October 2017: Flagging risk

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the fragmented approach to communicating additional risk minimisation measures for medicines. Article available here: http://dtb.bmj.com/content/55/10/1.
The editors also review the long-term safety of PPIs (http://dtb.bmj.com/content/55/10/117) and discuss the use of the live attenuated influenza vaccine for children (http://dtb.bmj.com/content/55/10/114).

September 2017: Vitamin D and adolescents: a forgotten ‘at risk’ group?

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss vitamin D deficiency in teenagers and highlight the challenge of implementing national recommendations on vitamin D intake in young people. Full article here: http://dtb.bmj.com/content/55/9/1.
The editors also review the management of scarlet fever (http://dtb.bmj.com/content/55/9/102.2) and consider two drugs (baricitinib and tofacitinib) recently licensed for the management of rheumatoid arthritis (http://dtb.bmj.com/content/55/9/102.1).

August 2017: What price drugs online?

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the supply of medicines from online primary care services (article here: http://dtb.bmj.com/content/55/8/85).
The editors also review two recently licensed drugs: eluxadoline, a mixed opioid receptor agonist/antagonist for irritable bowel syndrome (http://dtb.bmj.com/content/55/8/90) and an oral formulation of glycopyrronium (http://dtb.bmj.com/content/55/8/93) for severe drooling in children.

July 2017: The good, the bad and the ugly

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the role of Electroconvulsive Therapy (ECT) in the management of psychiatric disorders.
Article here: http://dtb.bmj.com/content/55/7/1.
The editors also discuss the use of liraglutide for obesity (related article here: http://dtb.bmj.com/content/55/7/78)and highlight some of the challenges associated with the management of people with clinical features of both asthma and COPD (http://dtb.bmj.com/content/55/7/66).